Advances in ophthalmology practice and research最新文献

英文中文

A two-year longitudinal observational study of the peripapillary microvasculature in pediatric type 1 diabetes mellitus patients without visual impairment or diabetic retinopathy 对无视力障碍或糖尿病视网膜病变的儿童 1 型糖尿病患者毛细血管周围进行为期两年的纵向观察研究

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.001

Lipu Cui, Chenhao Yang, Haidong Zou

引用次数: 0

TOC 技术选择委员会

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/S2667-3762(24)00015-5

引用次数: 0

Response to letter to the editor regarding "Is relying on RNFL specific enough to identify any changes in the CNS?" 回复致编辑的信，内容涉及 "依靠 RNFL 的特异性是否足以识别中枢神经系统的任何变化？

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.003

Hanfei Wu , Haishuang Lin , Mengting Ruan, Huanjie Fang, Nannan Dong, Tiewei Wang, Feifei Yu, Jiawei Zhao

引用次数: 0

Reply to the letter to the editor regarding “Is relying on RNFL specific enough to identify any changes in the CNS?” 回复致编辑的信，内容涉及 "依靠 RNFL 的特异性是否足以识别中枢神经系统的任何变化？

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.003

Hanfei Wu, Haishuang Lin, Mengting Ruan, Huanjie Fang, Nannan Dong, Tiewei Wang, Feifei Yu, Jiawei Zhao

引用次数: 0

Recent progress of nanomedicine in managing dry eye disease 纳米医学在治疗干眼症方面的最新进展

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.008

Zeen Lv , Su Li , Guixiang Zeng , Ke Yao , Haijie Han

Background

Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements. Fortunately, the advancements in nanomedicine offer effective solutions to address the aforementioned issues and provide significant assistance in the treatment of DED.

Main text

DED is considered a multifactorial disease of the ocular surface and tear film, in which the integrity of tear film function and structure plays a crucial role in maintaining the homeostasis of the ocular surface. The conventional treatment for DED involves the utilization of artificial tear products, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs. Furthermore, nanomedicine is presently a significant field of study, with numerous clinical trials underway for various nanotherapeutics including nanoemulsions, nanosuspensions, liposomes, and micelles. Notably, some of these innovative nanoformulations have already received FDA approval as novel remedies for DED, and the advancement of nanomedicine is poised to offer enhanced prospects to solve the shortcomings of existing treatments for DED partially.

Conclusions

This article provides an overview of the latest advancements in nanomedicine for DED treatment, while the field of DED treatment is expected to witness a remarkable breakthrough shortly with the development of nanomedicine, bringing promising prospects for patients worldwide suffering conditions.

背景干眼症（DED）是一种常见的眼部疾病，在最近的研究中备受关注。DED 的全球发病率从 5%到 50%不等，影响着全球很大一部分人，而且发病频率越来越高。虽然局部用药仍是眼部疾病的主流给药方法，但它存在生物利用度低、药物代谢快和给药要求频繁等缺点。正文DED被认为是眼表和泪膜的一种多因素疾病，其中泪膜功能和结构的完整性在维持眼表平衡方面起着至关重要的作用。DED 的传统治疗方法包括使用人工泪液产品、环孢素、皮质类固醇、粘蛋白促泌剂和非甾体抗炎药。此外，纳米医学目前也是一个重要的研究领域，各种纳米治疗药物（包括纳米乳剂、纳米悬浮剂、脂质体和胶束）的大量临床试验正在进行中。值得注意的是，其中一些创新型纳米制剂已获得美国食品及药物管理局（FDA）批准，可作为治疗 DED 的新型疗法，纳米医学的发展有望为部分解决现有 DED 治疗方法的不足之处提供更广阔的前景。结论本文概述了纳米医学在 DED 治疗方面的最新进展，随着纳米医学的发展，DED 治疗领域有望在短期内取得重大突破，为全球 DED 患者带来光明前景。

{"title":"Recent progress of nanomedicine in managing dry eye disease","authors":"Zeen Lv , Su Li , Guixiang Zeng , Ke Yao , Haijie Han","doi":"10.1016/j.aopr.2024.01.008","DOIUrl":"https://doi.org/10.1016/j.aopr.2024.01.008","url":null,"abstract":"<div><h3>Background</h3><p>Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements. Fortunately, the advancements in nanomedicine offer effective solutions to address the aforementioned issues and provide significant assistance in the treatment of DED.</p></div><div><h3>Main text</h3><p>DED is considered a multifactorial disease of the ocular surface and tear film, in which the integrity of tear film function and structure plays a crucial role in maintaining the homeostasis of the ocular surface. The conventional treatment for DED involves the utilization of artificial tear products, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs. Furthermore, nanomedicine is presently a significant field of study, with numerous clinical trials underway for various nanotherapeutics including nanoemulsions, nanosuspensions, liposomes, and micelles. Notably, some of these innovative nanoformulations have already received FDA approval as novel remedies for DED, and the advancement of nanomedicine is poised to offer enhanced prospects to solve the shortcomings of existing treatments for DED partially.</p></div><div><h3>Conclusions</h3><p>This article provides an overview of the latest advancements in nanomedicine for DED treatment, while the field of DED treatment is expected to witness a remarkable breakthrough shortly with the development of nanomedicine, bringing promising prospects for patients worldwide suffering conditions.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"4 1","pages":"Pages 23-31"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376224000088/pdfft?md5=ebc5ca87a18661140e0772d47574d08c&pid=1-s2.0-S2667376224000088-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139709483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy 微脉冲激光治疗中心性浆液性脉络膜视网膜病变失败后转用光导疗法

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.004

Maciej Gawęcki , Krzysztof Kiciński , Andrzej Grzybowski

Purpose

Subthreshold micropulse laser (SML) and photodynamic therapy (PDT) are among the most effective therapeutic modalities applied to central serous chorioretinopathy (CSCR). This study aimed to evaluate the efficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.

Methods

The study included 26 consecutive eyes of 24 patients (21 males and three females) with chronic CSCR. In all cases, a lack of reduction in subretinal fluid (SRF) levels was noted after at least two consecutive SML sessions. The parameters of best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT) were evaluated at baseline and 1, 3 and 12 months post-PDT.

Results

The mean duration of symptoms in the group was 53.81 ± 39.48 months, the mean age of the patients was 49.26 ± 12.91 years, and the mean subfoveal choroidal thickness (SFCT) was 572.11 ± 116.21 mm. Complete resorption of SRF was observed in 21 out of 26 eyes (80.77%) at 1 month and sustained in 18 cases (69.23%) at 12 months. At 12 months, in the sustained group, BCVA improved significantly from 0.39 ± 0.18 to 0.19 ± 0.2 logMAR (P = 0.01), central subfoveal thickness (CST) reduced from 316.44 ± 75.83 mm to 197.67 ± 22.99 mm (P < 0.0001), and SFCT reduced from 579.28 mm to 446.78 mm (P < 0.0001).

Conclusions

PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment. Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology. Thus, PDT should be considered for patients with prominently increased choroidal thickness.

目的阈下微脉冲激光（SML）和光动力疗法（PDT）是治疗中心性浆液性脉络膜视网膜病变（CSCR）最有效的治疗方法之一。本研究旨在评估光动力疗法对至少两次 SML 治疗无效的 CSCR 病例的疗效和持久性。在所有病例中，经过至少两次连续的 SML 治疗后，视网膜下积液（SRF）水平均未下降。结果该组患者的平均病程为（53.81±39.48）个月，平均年龄为（49.26±12.91）岁，平均视网膜下脉络膜厚度（SFCT）为（572.11±116.21）毫米。26只眼睛中有21只（80.77%）在1个月时观察到SRF完全吸收，18只（69.23%）在12个月时观察到SRF持续吸收。12 个月时，持续组的 BCVA 从 0.39 ± 0.18 显著改善到 0.19 ± 0.2 logMAR（P = 0.01），中央眼底厚度（CST）从 316.44 ± 75.83 mm 减少到 197.结论PDT为成功治疗对SML治疗无反应的CSCR提供了机会。即使是症状持续时间较长、视网膜形态发生显著改变的病例，也有可能获得改善。因此，脉络膜厚度明显增加的患者应考虑使用 PDT。

{"title":"Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy","authors":"Maciej Gawęcki , Krzysztof Kiciński , Andrzej Grzybowski","doi":"10.1016/j.aopr.2024.01.004","DOIUrl":"10.1016/j.aopr.2024.01.004","url":null,"abstract":"<div><h3>Purpose</h3><p>Subthreshold micropulse laser (SML) and photodynamic therapy (PDT) are among the most effective therapeutic modalities applied to central serous chorioretinopathy (CSCR). This study aimed to evaluate the efficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.</p></div><div><h3>Methods</h3><p>The study included 26 consecutive eyes of 24 patients (21 males and three females) with chronic CSCR. In all cases, a lack of reduction in subretinal fluid (SRF) levels was noted after at least two consecutive SML sessions. The parameters of best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT) were evaluated at baseline and 1, 3 and 12 months post-PDT.</p></div><div><h3>Results</h3><p>The mean duration of symptoms in the group was 53.81 ± 39.48 months, the mean age of the patients was 49.26 ± 12.91 years, and the mean subfoveal choroidal thickness (SFCT) was 572.11 ± 116.21 mm. Complete resorption of SRF was observed in 21 out of 26 eyes (80.77%) at 1 month and sustained in 18 cases (69.23%) at 12 months. At 12 months, in the sustained group, BCVA improved significantly from 0.39 ± 0.18 to 0.19 ± 0.2 logMAR (<em>P</em> = 0.01), central subfoveal thickness (CST) reduced from 316.44 ± 75.83 mm to 197.67 ± 22.99 mm (<em>P</em> < 0.0001), and SFCT reduced from 579.28 mm to 446.78 mm (<em>P</em> < 0.0001).</p></div><div><h3>Conclusions</h3><p>PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment. Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology. Thus, PDT should be considered for patients with prominently increased choroidal thickness.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"4 1","pages":"Pages 32-38"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376224000040/pdfft?md5=d6e2139d9e4970a2e57c228e7f858403&pid=1-s2.0-S2667376224000040-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139631916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating for unrecognized deficits in perimetry associated with functional upper eyelid malposition 评估与功能性上眼睑位置不正有关的未识别的视力缺陷

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.007

Linyan Wang, Davin C. Ashraf, Michael Deiner, Oluwatobi O. Idowu, Seanna R. Grob, Bryan J. Winn, M. Vagefi, Robert C. Kersten

引用次数: 0

An assessment of the capability of ChatGPT in solving clinical cases of ophthalmology using multiple choice and short answer questions 评估 ChatGPT 使用选择题和简答题解决眼科临床病例的能力

Advances in ophthalmology practice and research

Pub Date : 2024-01-19 DOI: 10.1016/j.aopr.2024.01.005

Anjana Christy Alexander , Suprithy Somineni Raghupathy , Krishna Mohan Surapaneni

引用次数: 0

Is relying on RNFL specific enough to identify any changes in the CNS? 依靠 RNFL 的特异性是否足以识别中枢神经系统的任何变化？

Advances in ophthalmology practice and research

Pub Date : 2024-01-17 DOI: 10.1016/j.aopr.2024.01.002

Dzakky Avecienna Nur Faridwazdi, Yuliono Trika Nur Hasan, Alvi Milliana, Zulvikar Syambani Ulhaq

引用次数: 0

Evaluation of choroidal thickness and retinal nerve fiber layer thickness in Chinese pregnant women and healthy non-pregnant women 评估中国孕妇和健康非孕妇的脉络膜厚度和视网膜神经纤维层厚度

Advances in ophthalmology practice and research

Pub Date : 2023-12-06 DOI: 10.1016/j.aopr.2023.12.001

Hanfei Wu , Haishuang Lin , Mengting Ruan , Huanjie Fang , Nannan Dong , Tiewei Wang , Feifei Yu , Jiawei Zhao

Purpose

To evaluate choroidal thickness and retinal nerve fiber layer (RNFL) thickness in different trimesters using enhanced depth imaging optical coherence tomography (EDI-OCT).

Methods

A prospective comparative study included 45 healthy pregnant women in the first trimester, 45 women in the second, 45 women in the third and 45 healthy non-pregnant women as the control group. Macular choroidal thickness was measured at three locations: The subfoveal, 1 mm temporal, and 1 mm nasal from the fovea with EDI-OCT. Peripapillary choroidal thickness (PPCT) and RNFL thickness parameters were automatically calculated by the Spectralis OCT.

Results

The subfoveal, temporal and nasal macular choroidal thickness were all significantly thicker in the second trimester, compared with those parameters in the first, the third trimesters and the control group (all P < 0.05). The PPCT was significantly increased in the second trimeter compared with the control group at global, temporal, temporal inferior, nasal and nasal inferior positions (all P < 0.05). The RNFL thickness was also significantly increased in pregnant women at nasal superior and nasal inferior quadrants (all P < 0.05).

Conclusions

The choroidal thickness in pregnant women was found to be thicker than the control group, regardless of macular or optic disc location. Findings of RNFL thickening might indicate subclinical involvement of the central nervous system.

目的使用增强型深度成像光学相干断层扫描（EDI-OCT）评估不同孕期的脉络膜厚度和视网膜神经纤维层（RNFL）厚度。方法一项前瞻性比较研究纳入了 45 名健康孕妇，包括孕期前三个月的孕妇、孕期后三个月的孕妇、孕期前三个月的孕妇以及作为对照组的 45 名健康非孕妇。在三个位置测量黄斑脉络膜厚度：使用 EDI-OCT 在三个位置测量黄斑脉络膜厚度：眼窝下、距离眼窝 1 毫米的颞侧和 1 毫米的鼻侧。结果与妊娠头三个月、妊娠三个月和对照组相比，妊娠后三个月的眼底、颞侧和鼻侧黄斑脉络膜厚度均明显增厚（均为 P <0.05）。与对照组相比，妊娠中期的 PPCT 在全球、颞、颞下、鼻和鼻下位置均明显增加（均为 P < 0.05）。结论无论黄斑或视盘位置如何，孕妇的脉络膜厚度都比对照组厚。RNFL增厚的发现可能表明中枢神经系统受到亚临床影响。

{"title":"Evaluation of choroidal thickness and retinal nerve fiber layer thickness in Chinese pregnant women and healthy non-pregnant women","authors":"Hanfei Wu , Haishuang Lin , Mengting Ruan , Huanjie Fang , Nannan Dong , Tiewei Wang , Feifei Yu , Jiawei Zhao","doi":"10.1016/j.aopr.2023.12.001","DOIUrl":"10.1016/j.aopr.2023.12.001","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate choroidal thickness and retinal nerve fiber layer (RNFL) thickness in different trimesters using enhanced depth imaging optical coherence tomography (EDI-OCT).</p></div><div><h3>Methods</h3><p>A prospective comparative study included 45 healthy pregnant women in the first trimester, 45 women in the second, 45 women in the third and 45 healthy non-pregnant women as the control group. Macular choroidal thickness was measured at three locations: The subfoveal, 1 mm temporal, and 1 mm nasal from the fovea with EDI-OCT. Peripapillary choroidal thickness (PPCT) and RNFL thickness parameters were automatically calculated by the Spectralis OCT.</p></div><div><h3>Results</h3><p>The subfoveal, temporal and nasal macular choroidal thickness were all significantly thicker in the second trimester, compared with those parameters in the first, the third trimesters and the control group (all <em>P</em> < 0.05). The PPCT was significantly increased in the second trimeter compared with the control group at global, temporal, temporal inferior, nasal and nasal inferior positions (all <em>P</em> < 0.05). The RNFL thickness was also significantly increased in pregnant women at nasal superior and nasal inferior quadrants (all <em>P</em> < 0.05).</p></div><div><h3>Conclusions</h3><p>The choroidal thickness in pregnant women was found to be thicker than the control group, regardless of macular or optic disc location. Findings of RNFL thickening might indicate subclinical involvement of the central nervous system.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"4 1","pages":"Pages 8-13"},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376223000628/pdfft?md5=e1acd14582585864316213ce1a25fe6e&pid=1-s2.0-S2667376223000628-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138625448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Advances in ophthalmology practice and research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀